Molecular complexes and compositions containing the same are disclosed herein. More specifically, carbohydrate polymers, for example hyaluronic acid or a salt thereof, are complexed with a biologically active compound selected from natural products and nutrients (amino acids, amino esters, hydroxy acids, hydroxy esters, vitamins, cannabinoids, etc.), and active pharmaceutical ingredients to create stabilized molecular complexes. The complexation can be conveniently achieved by means of a resonant acoustic mixing process.

Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.

A pharmaceutical composition is provided that is useful to enhance the repair of articular cartilage, to treat a joint injury or to prevent, inhibit or treat osteoarthritis in a mammal. The composition may include an effective amount of an isolated protein that is a chemoattractant for chondrogenic progenitor cells and/or an effective amount of an isolated protein that is a chondro genic factor or a nucleic acid sequence that encodes a chondrogenic factor.

The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

A gold particle having at least one cross-section in the range of 20-1000 μnm and having a purity greater than 99.00% w/w, preferably 99.99% w/w for use in treatment of a wound to minimize scar formation and to prevent abnormal scar formation. A composition comprising at least one gold particle having at least one cross-section in the range of 20-1000 μm and having a purity greater than 99.00% w/w, preferably 99.99% w/w for use in treatment of a wound to prevent abnormal scar formation, wherein the composition further comprises hyaluronic acid or any other physiologically acceptable carrier.

Aggregates formed from one or both of chitosan and hyaluronan, suspended or otherwise dispersed in a liquid carrier are useful for treating joint or muscle distress in a subject, where the composition may include one or more pharmaceutically active agents and the composition in locally delivered to the joint or muscle by, for example, injection.

Disclosed herein are stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Celecoxib, its salts, or derivatives thereof, which is useful in the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain especially in cancer related acute pain, primary dysmenorrhea. More specifically, the complexes possess instantaneous redispersibility, increased apparent solubility and permeability that provide faster onset of action for acute pain relief and lower GI related side effects. Further disclosed are methods of formulating and manufacturing the complexes described herein, pharmaceutical compositions, and uses and methods of treatment.

The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R.sup.1, R.sup.2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.

##STR00001##

The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments.